Priunta 150mg

Priunta 150MG Inj is a brand name for Trastuzumab, which is a medication used to treat certain types of cancer. Here are some key points about the product:

Composition:

Trastuzumab is a recombinant humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2) and inhibits its effects.

Indications:

Trastuzumab is indicated for the treatment of:

1. Metastatic breast cancer (in combination with paclitaxel)
2. Metastatic gastric cancer (in combination with chemotherapy)
3. Adjuvant breast cancer (in combination with docetaxel and fluorouracil)

Mechanism of Action:

Trastuzumab works by:

1. Binding to HER2 and inhibiting its ability to bind to its receptors
2. Inhibiting the growth and proliferation of cancer cells that overexpress HER2

Dosage and Administration:

The recommended dosage of Trastuzumab is:

• 150mg administered as an intravenous infusion every 3 weeks
• The dosage may be adjusted depending on the patient’s response to treatment

Side Effects:

Common side effects of Trastuzumab include:

1. Infusion-related reactions (e.g., fever, chills, nausea, vomiting)
2. Fatigue
3. Headache
4. Nausea
5. Abdominal pain
6. Rash or skin changes
7. Heart problems (e.g., congestive heart failure, left ventricular dysfunction)

Serious side effects can include:

1. Cardiac problems (e.g., cardiomyopathy, heart failure)
2. Severe allergic reactions
3. Hemolytic anemia or thrombocytopenia
4. Gastrointestinal perforation or bleeding
5. Severe respiratory reactions

Contraindications:

Trastuzumab is contraindicated in patients with:

1. Known hypersensitivity to trastuzumab
2. History of severe cardiac disease or cardiac dysfunction
3. Pregnancy or breastfeeding (unless absolutely necessary)
4. Severe liver disease

Precautions:

1. Patients with a history of cardiac disease or cardiac dysfunction should be closely monitored while receiving Trastuzumab.
2. Patients with a history of liver disease or kidney dysfunction should receive dose reduction or close monitoring while receiving Trastuzumab.
3. Patients with a history of blood disorders should be closely monitored for signs of blood dyscrasias.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of infection, such as fever, chills, or sore throat.
• Patients should be advised to report any changes in their appetite, nausea, or vomiting.
• Patients should be informed that they may experience bleeding or bruising during treatment.

Storage and Handling:

• Store vials at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 28 days of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.